(NASDAQ: FTH) Faeth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Faeth Therapeutics's earnings in 2026 is -$195,529,000.On average, 15 Wall Street analysts forecast FTH's earnings for 2026 to be -$599,009,476, with the lowest FTH earnings forecast at -$3,437,934,176, and the highest FTH earnings forecast at -$81,126,014. On average, 15 Wall Street analysts forecast FTH's earnings for 2027 to be -$85,686,849, with the lowest FTH earnings forecast at -$125,630,978, and the highest FTH earnings forecast at -$70,001,711.
In 2028, FTH is forecast to generate -$91,772,269 in earnings, with the lowest earnings forecast at -$141,205,002 and the highest earnings forecast at -$66,745,818.